Neutral on Dr Reddy's Lab, target Rs 2275: Motilal Oswal Securities
Neutral on Dr. Reddy's Laboratories Ltd. at a price target of Rs 2275.0 .

Investment rationale by Motilal Oswal
Although the approval of gSuboxone is positive news for DRRD, the recent run-up in the stock already factors in this event. We maintain Neutral rating on the stock with a target price of INR2,275 @18x FY20E PER (v/s INR2,000 @18x FY20 PER). We have increased our EPS for FY19/20E by 16/14% as we build in the impact of earlylaunch of Suboxone (earlier assumption of launch by 4QFY19E).
Download ET Markets APP